1. Home
  2. ANNX vs CAC Comparison

ANNX vs CAC Comparison

Compare ANNX & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.87

Market Cap

730.4M

Sector

Health Care

ML Signal

HOLD

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$50.82

Market Cap

781.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANNX
CAC
Founded
2011
1875
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
730.4M
781.2M
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
ANNX
CAC
Price
$5.87
$50.82
Analyst Decision
Strong Buy
Buy
Analyst Count
6
2
Target Price
$16.50
$45.50
AVG Volume (30 Days)
2.4M
84.2K
Earning Date
05-11-2026
04-28-2026
Dividend Yield
N/A
3.28%
EPS Growth
N/A
6.08
EPS
N/A
3.84
Revenue
N/A
$41,739,000.00
Revenue This Year
N/A
$19.15
Revenue Next Year
$22,605.10
$6.05
P/E Ratio
N/A
$13.35
Revenue Growth
N/A
16.96
52 Week Low
$1.40
$35.00
52 Week High
$7.18
$51.57

Technical Indicators

Market Signals
Indicator
ANNX
CAC
Relative Strength Index (RSI) 55.27 69.58
Support Level $4.79 $41.94
Resistance Level $6.50 $51.36
Average True Range (ATR) 0.44 1.11
MACD 0.09 0.52
Stochastic Oscillator 66.67 90.72

Price Performance

Historical Comparison
ANNX
CAC

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

Share on Social Networks: